Drugs Made In America Acquisition II Corp.
DMIIRNasdaq
$0.08
↑ +3.1%Jul 16 close · end-of-day
Price
1Y↓ -47.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
—
Enterprise Value
—
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
$8.6M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-48.2%
ROIC
—
Debt / Equity
-0.0
Net Cash
-$102,280.00
Return 1Y
—
Company profile
Management & directors
- Stockwell LynnCEO and Exe. Chair of Board
- Worman Glenn C.CFO
Roles derived from SEC Form 4 filings.
Earnings
DMIIR Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS——
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2025 |
|---|---|
| Revenue | — |
| Gross profit | — |
| Operating income | -$488,385.00 |
| Net income | $4.2M |
| Diluted EPS | — |
| Operating cash flow | -$1.0M |
| Free cash flow | — |
| Gross margin | — |
| Operating margin | — |
| Net margin | — |
| Line item | Q1 '25 | Q3 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$59,327.00 | — | -$155,513.00 | — | -$132,030.00 |
| Net income | -$59,327.00 | -$38,073.00 | -$46,158.00 | $4.3M | $4.3M |
| Diluted EPS | — | — | — | — | — |
| Operating cash flow | -$10,044.00 | — | — | — | -$102,503.00 |
| Free cash flow | — | — | — | — | — |
| Gross margin | — | — | — | — | — |
| Operating margin | — | — | — | — | — |
| Net margin | — | — | — | — | — |
Company news
Coming soonHeadlines for DMIIR will appear here once the news feed is connected.
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-09-26 | Do Catherine | J | 100,000 | — | — | filing |
| 2025-09-26 | Shulgan Myron W. | J | 100,000 | — | — | filing |
| 2025-09-26 | Worman Glenn C.· CFO | J | 100,000 | — | — | filing |
| 2025-09-26 | Stockwell Lynn· CEO and Exe. Chair of Board | Buy | 700,000 | — | — | filing |
| 2025-09-26 | Stockwell Lynn· CEO and Exe. Chair of Board | J | 400,000 | — | — | filing |
| 2025-09-26 | Stockwell Lynn· CEO and Exe. Chair of Board | Sale | 7,966,667 | — | — | filing |
| 2025-09-26 | Drugs Made In America Acquisition II LLC | Buy | 700,000 | — | — | filing |
| 2025-09-26 | Drugs Made In America Acquisition II LLC | J | 400,000 | — | — | filing |
| 2025-09-26 | Drugs Made In America Acquisition II LLC | Sale | 7,966,667 | — | — | filing |
| 2025-09-26 | Prasad Sridhar G. | J | 100,000 | — | — | filing |
Latest 10 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.